^
    1d
    Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) (clinicaltrials.gov)
    P2, N=40, Recruiting, The First Affiliated Hospital of Xiamen University
    New P2 trial • Metastases
    |
    cisplatin • docetaxel • Tevimbra (tislelizumab) • Partruvix (pamiparib) • goserelin acetate • Airui'en (rezvilutamide)
    2d
    Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study. (PubMed, Int J Gynecol Cancer)
    To evaluate the efficacy and safety of biomarker-driven combinatorial therapies of pamiparib, tislelizumab, bevacizumab, and nab-paclitaxel in platinum-resistant, recurrent ovarian cancer. Recruitment is estimated to be completed by 2024 and results may be published by 2027. ClinicalTrials.gov: NCT05044871.
    Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CD8 (cluster of differentiation 8)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA wild-type
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab) • albumin-bound paclitaxel • Partruvix (pamiparib)
    11d
    Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=44, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting
    Enrollment open • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • CHEK2 (Checkpoint kinase 2) • RAD50 (RAD50 Double Strand Break Repair Protein) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CHEK1 (Checkpoint kinase 1) • EMSY (EMSY Transcriptional Repressor BRCA2 Interacting)
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation • RAD50 mutation • CHEK1 mutation • CHEK1 expression
    |
    Cabometyx (cabozantinib tablet) • Partruvix (pamiparib)
    2ms
    BGB-290-102: Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=128, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Partruvix (pamiparib)
    2ms
    Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=40, Recruiting, Affiliated Hospital of Jiangnan University | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Nov 2023 --> Nov 2024
    Trial completion date • Trial primary completion date
    |
    Partruvix (pamiparib)
    2ms
    Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=44, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • CHEK2 (Checkpoint kinase 2) • RAD50 (RAD50 Double Strand Break Repair Protein) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CHEK1 (Checkpoint kinase 1) • EMSY (EMSY Transcriptional Repressor BRCA2 Interacting)
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation • RAD50 mutation • CHEK1 mutation • CHEK1 expression
    |
    Cabometyx (cabozantinib tablet) • Partruvix (pamiparib)
    3ms
    BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations (clinicaltrials.gov)
    P1/2, N=60, Completed, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Suspended --> Completed
    Trial completion
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH1 R132 • IDH2 R140 • IDH2 R172
    |
    temozolomide • Partruvix (pamiparib)
    3ms
    A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, Zhejiang Cancer Hospital | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Partruvix (pamiparib)
    5ms
    Advances in Development of Selective Antitumor Inhibitors That Target PARP-1. (PubMed, J Med Chem)
    The currently approved PARP inhibitors include olaparib, niraparib, rucaparib, talazoparib, fuzuloparib, and pamiparib. The present review introduces the necessity for research on the development of selective PARP-1 inhibitors from the perspective of structural and functional mechanisms of PARP-1 inhibition. A review of recently reported selective PARP-1 inhibitors provides the foundation for exploring novel strategies for designing selective PARP-1 inhibitors from the perspective of structure-activity relationships combined with computer simulations.
    Review • Journal
    |
    PARP2 (Poly(ADP-Ribose) Polymerase 2)
    |
    Lynparza (olaparib) • Talzenna (talazoparib) • Zejula (niraparib) • Rubraca (rucaparib) • Partruvix (pamiparib) • AiRuiYi (fluzoparib)
    5ms
    BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations (clinicaltrials.gov)
    P1/2, N=60, Suspended, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Oct 2023 --> Dec 2023 | Trial primary completion date: Oct 2023 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH1 R132 • IDH2 R140 • IDH2 R172
    |
    temozolomide • Partruvix (pamiparib)
    6ms
    Phase II and Phase 0 results of ABTC 1801: a multi-arm clinical trial of the PARP inhibitor pamiparib with very low dose metronomic temozolomide in recurrent IDH mutant gliomas (SNO 2023)
    While pamiparib appeared to achieve sufficient pharmacologically active concentrations in both enhancing and non-enhancing tumors, combination with temozolomide did not produce a meaningful ORR in IDHmt recurrent gliomas. Cumulative hematologic toxicity was substantial.
    Clinical • P2 data • BRCA Biomarker • PARP Biomarker
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    IDH1 mutation
    |
    temozolomide • Partruvix (pamiparib)
    6ms
    Development and validation of a sensitive LC-MS/MS method for the assay of four PARP inhibitors in human plasma and its application in ovarian cancer patients. (PubMed, J Pharm Biomed Anal)
    In this study, we established and validated a liquid chromatography-tandem mass spectrometry (LC-MS/MS) based method to simultaneously quantify the four frequently prescripted PARP inhibitors, namely niraparib, olaparib，fluzoparib, and pamiparib, in ovarian cancer. The mean plasma concentrations (±SD) of niraparib and olaparib were 424.76 (±228.35) ng/mL and 1760.47 (±1739.69) ng/mL, respectively. The validated LC-MS/MS method allows the convient and efficient determination of four PARP inhibitors' exposure levels in ovarian cancer patients.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    Lynparza (olaparib) • Zejula (niraparib) • Partruvix (pamiparib) • AiRuiYi (fluzoparib)
    6ms
    Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells. (PubMed, J Neurooncol)
    Our study identifies the combination of entinostat with olaparib as a new potential therapeutic approach for MYC-driven Group 3 MB.
    Journal • PARP Biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    MYC amplification
    |
    Lynparza (olaparib) • doxorubicin hydrochloride • Kisqali (ribociclib) • Xpovio (selinexor) • Partruvix (pamiparib) • idasanutlin (RG7388) • Jingzhuda (entinostat) • vinblastine
    6ms
    PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics. (PubMed, Semin Oncol)
    Currently, four agents, namely olaparib, rucaparib, niraparib, and talazoparib, have obtained approval in the United States and Europe. Additionally, this review briefly covers veliparib, a PARP inhibitor under development, and two recently approved PARP inhibitors in China, fuzuloparib and pamiparib. Although significant progress has been made in understanding PARP inhibitors, there are several unanswered questions that remain, necessitating further research across a broader spectrum of cancer types within this evolving class of anticancer agents.
    PK/PD data • Review • Journal • PARP Biomarker
    |
    PARP2 (Poly(ADP-Ribose) Polymerase 2)
    |
    Lynparza (olaparib) • Talzenna (talazoparib) • Zejula (niraparib) • Rubraca (rucaparib) • veliparib (ABT-888) • Partruvix (pamiparib) • AiRuiYi (fluzoparib)
    7ms
    BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations (clinicaltrials.gov)
    P1/2, N=60, Suspended, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active, not recruiting --> Suspended
    Trial suspension
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH1 R132 • IDH2 R140 • IDH2 R172
    |
    temozolomide • Partruvix (pamiparib)
    7ms
    Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, University of Chicago | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Tevimbra (tislelizumab) • Partruvix (pamiparib) • hydroxyurea • fluorouracil topical
    7ms
    A Combined Phase 0/2 "Trigger" Trial Evaluating Pamiparib or Olaparib with Concurrent Radiotherapy in Patients with Newly-Diagnosed or Recurrent Glioblastoma. (PubMed, Int J Radiat Oncol Biol Phys)
    Pamiparib achieved pharmacologically-relevant concentrations in nonenhancing GBM tissue and suppressed induction of PAR levels ex vivo post-radiation. The majority of patients with MGMT-unmethylated GBM advanced to the phase 2 portion of the trial, and pamiparib was generally well-tolerated in these patients.
    Journal • PARP Biomarker
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    Lynparza (olaparib) • Partruvix (pamiparib)
    7ms
    A Combined Phase 0/2 "Trigger" Trial Evaluating Pamiparib or Olaparib with Concurrent Radiotherapy in Patients with Newly-Diagnosed or Recurrent Glioblastoma (ASTRO 2023)
    Pamiparib achieved pharmacologically-relevant concentrations in nonenhancing GBM tissue and suppressed induction of PAR levels ex vivo post-radiation. The majority of patients with MGMT-unmethylated GBM advanced to the phase 2 portion of the trial, and pamiparib was generally well-tolerated in these patients.
    Clinical • PARP Biomarker
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    Lynparza (olaparib) • Partruvix (pamiparib)
    8ms
    Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial. (PubMed, Br J Cancer)
    Pamiparib plus tislelizumab showed a variable level of antitumour activity in patients with advanced solid tumours, with the highest ORR in TNBC and was associated with a manageable safety profile.
    P1 data • Journal • Combination therapy • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    BRCA2 mutation • BRCA1 mutation • HRD
    |
    Tevimbra (tislelizumab) • Partruvix (pamiparib)
    9ms
    Pamiparib combined with surufatinib as a neoadjuvant therapy for advanced ovarian cancer patients in the entire population: Preliminary results of a prospective, exploratory, single-arm phase II clinical study (ESMO 2023)
    Conclusions Pamiparib combined with Surufatinib as a new neoadjuvant "chemotherapy-free" regimen showed extremely high R0 and ORR rates with manageable toxicity profiles. Currently, the experiment is still ongoing and further analysis and reporting of more data will be conducted.
    Clinical • P2 data • BRCA Biomarker • PARP Biomarker • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA2 mutation • BRCA1 mutation • HRD
    |
    Partruvix (pamiparib) • Sulanda (surufatinib)
    10ms
    Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results. (PubMed, Cancer Med)
    Maintenance pamiparib did not meet statistical significance for superiority versus placebo for PFS, but was well tolerated with few treatment discontinuations; no unexpected safety signals were identified.
    P2 data • Journal • PARP Biomarker • Metastases
    |
    PARP2 (Poly(ADP-Ribose) Polymerase 2)
    |
    Partruvix (pamiparib)
    11ms
    BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations (clinicaltrials.gov)
    P1/2, N=60, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jul 2023 --> Oct 2023 | Trial primary completion date: Apr 2023 --> Oct 2023
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH1 R132 • IDH2 R140 • IDH2 R172
    |
    temozolomide • Partruvix (pamiparib)
    11ms
    BGB-290-103: Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1b, N=139, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    AR (Androgen receptor) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    temozolomide • Partruvix (pamiparib)
    11ms
    FLASH radiotherapy and PARP inhibition on preclinical models of glioblastoma and neurotoxicity (ESTRO 2023)
    Material and Methods Mice were randomly allocated to the following groups: 1) control; 2) FLASH irradiation (FLASH IR, mean dose rate= 2000 Gy/s); 3) Conventional dose rate irradiation (CONV IR, 0.1 Gy/s); 4) PARP inhibitor (PARPi, pamiparib, oral gavage, 12.5 mg/kg, twice daily for 7 days); 5) PARPi+CONV IR; and 6) PARPi+FLASH IR...However, the combination of PARPi+CONV IR was also associated with increased acute systemic toxicity. Overall, this research demonstrates the potential of using FLASH radiotherapy together with PARP inhibitors for the treatment of glioblastoma.
    Preclinical
    |
    Partruvix (pamiparib)
    12ms
    Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, Jonsson Comprehensive Cancer Center | N=21 --> 0 | Trial completion date: Aug 2024 --> May 2023 | Recruiting --> Withdrawn
    Enrollment change • Trial completion date • Trial withdrawal
    |
    FH (Fumarate Hydratase)
    |
    temozolomide • Partruvix (pamiparib)
    1year
    Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, University of Chicago | Initiation date: Nov 2022 --> Nov 2023
    Trial initiation date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Tevimbra (tislelizumab) • Partruvix (pamiparib) • hydroxyurea • fluorouracil topical
    1year
    Advanced ovarian clear cell carcinoma with RAD50 mutation treated by PARP inhibitor pamiparib combined with anti-angiogenesis therapy: a case report. (PubMed, Anticancer Drugs)
    Next, the patient had received targeted combination therapy with poly (ADP-ribose) polymerase (PARP) inhibitor pamiparib and bevacizumab, achieving partial remission. To date, the patient has been followed up for more than half a year with favorable survival and high quality of life. The case report suggested that parmiparib-targeted therapy is a viable treatment option for advanced OCCC patients with RAD50 mutation.
    Journal • PARP Biomarker • Metastases
    |
    HRD (Homologous Recombination Deficiency) • RAD50 (RAD50 Double Strand Break Repair Protein)
    |
    RAD50 mutation
    |
    Avastin (bevacizumab) • Partruvix (pamiparib)
    over1year
    Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy (clinicaltrials.gov)
    P2, N=46, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    tamoxifen • Partruvix (pamiparib)
    over1year
    Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer (clinicaltrials.gov)
    P2, N=20, Recruiting, Bai-Rong Xia
    New P2 trial • Metastases
    |
    HRD (Homologous Recombination Deficiency)
    |
    Partruvix (pamiparib) • Sulanda (surufatinib)
    over1year
    Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study. (PubMed, Breast Cancer Res Treat)
    Pamiparib showed encouraging efficacy and an acceptable safety profile in patients with locally advanced and metastatic HER2- breast cancer with gBRCA1/2 m.
    Clinical • P2 data • Journal • BRCA Biomarker • PARP Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • BRCA mutation
    |
    Partruvix (pamiparib)
    over1year
    H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models. (PubMed, J Clin Invest)
    We treated H3.3-G34R pHGG-bearing mice with a combination of radiotherapy (RT) and DNA damage response inhibitors (DDRi) (i.e., the blood-brain barrier-permeable PARP inhibitor pamiparib and the cell-cycle checkpoint CHK1/2 inhibitor AZD7762), and these combinations resulted in long-term survival for approximately 50% of the mice. Long-term survivors developed immunological memory, preventing pHGG growth upon rechallenge. These results demonstrate that DDRi and STING agonists in combination with RT induce immune-mediated therapeutic efficacy in G34-mutant pHGG.
    Journal • PARP Biomarker
    |
    STING (stimulator of interferon response cGAMP interactor 1) • CGAS (Cyclic GMP-AMP Synthase)
    |
    Partruvix (pamiparib) • AZD-7762
    over1year
    A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Hongqian Guo | Active, not recruiting --> Recruiting
    Enrollment open
    |
    HRD (Homologous Recombination Deficiency)
    |
    abiraterone acetate • Partruvix (pamiparib)
    over1year
    Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy. (PubMed, Oncotarget)
    The efficacy of poly ADP-ribose polymerase inhibitors (PARPis) and temozolomide (TMZ), alone and in combination, was evaluated both in vitro and in vivo. In vivo, treatment with standard dosing of the PARP inhibitor BGB-290 and low-dose TMZ significantly inhibits tumor growth without a significant increase in toxicity. These findings provide the basis for a novel therapeutic strategy exploiting HR deficiency in FH and SDH-deficient RCC with combined PARP inhibition and low-dose alkylating chemotherapy.
    Journal • PARP Biomarker
    |
    SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • FH (Fumarate Hydratase) • KDM4A (Lysine Demethylase 4A)
    |
    temozolomide • Partruvix (pamiparib)
    over1year
    Next-generation sequencing (NGS) for identifying actionable molecular alterations in newly diagnosed and recurrent IDHwt-glioblastoma (GBM) patients: a large mono institutional experience (SNO 2022)
    All patients received radiotherapy and/or temozolomide as first line therapy...To date, 10% of patients received a personalized treatment as compassionate use, off-label use or in clinical trials (9 Dabrafenib/Trametinib, 8 Alpelisib, 3 Erdafitinib, 2 Ipatasertib, 1 Alectinib, 1 Capmatinib, 1 Palbociclib, 1 Entrectinib, 1 Pamiparib)...The activity analysis is ongoing. However, the incidence of actionable molecular alterations may differ between diagnosis and recurrent GBM samples.
    Clinical • Tumor mutational burden • PARP Biomarker • BRCA Biomarker • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • FGFR1 (Fibroblast growth factor receptor 1) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • CDK4 (Cyclin-dependent kinase 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    BRAF V600E • EGFR mutation • TMB-H • PIK3CA mutation • BRAF V600 • EGFR amplification • NF1 mutation • IDH wild-type • EGFR mutation + PTEN mutation
    |
    FoundationOne® CDx
    |
    Mekinist (trametinib) • Ibrance (palbociclib) • Tafinlar (dabrafenib) • Rozlytrek (entrectinib) • temozolomide • Alecensa (alectinib) • Piqray (alpelisib) • Balversa (erdafitinib) • ipatasertib (RG7440) • Tabrecta (capmatinib) • Partruvix (pamiparib)
    over1year
    Next-generation sequencing (NGS) for identifying actionable molecular alterations in newly diagnosed and recurrent IDHwt-glioblastoma (GBM) patients: a large mono institutional experience (EANO 2022)
    All patients received radiotherapy and/or temozolomide as first line therapy...To date, 10% of patients received a personalized treatment as compassionate use, off-label use or in clinical trials (9 Dabrafenib/Trametinib, 8 Alpelisib, 3 Erdafitinib, 2 Ipatasertib, 1 Alectinib, 1 Capmatinib, 1 Palbociclib, 1 Entrectinib, 1 Pamiparib)... NGS is feasible in GBM samples. Potentially, a high rate of patients could receive a personalized treatment. The activity analysis is ongoing.
    Clinical • Tumor mutational burden • PARP Biomarker • BRCA Biomarker • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • FGFR1 (Fibroblast growth factor receptor 1) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • CDK4 (Cyclin-dependent kinase 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    BRAF V600E • EGFR mutation • TMB-H • PIK3CA mutation • BRAF V600 • EGFR amplification • NF1 mutation • IDH wild-type • EGFR mutation + PTEN mutation
    |
    FoundationOne® CDx
    |
    Mekinist (trametinib) • Ibrance (palbociclib) • Tafinlar (dabrafenib) • Rozlytrek (entrectinib) • temozolomide • Alecensa (alectinib) • Piqray (alpelisib) • Balversa (erdafitinib) • ipatasertib (RG7440) • Tabrecta (capmatinib) • Partruvix (pamiparib)
    over1year
    Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, University of Chicago
    New P1 trial • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Tevimbra (tislelizumab) • Partruvix (pamiparib) • hydroxyurea • fluorouracil topical
    over1year
    Development and validation of a liquid chromatography coupled with tandem mass spectrometry method for determining total and unbound pamiparib in human plasma and brain tumors. (PubMed, Biomed Chromatogr)
    Pamiparib was stable in plasma at -80°C for at least 6 months. The method was successfully applied to assess the plasma and tumor pharmacokinetics of total and unbound pamiparib in glioma patients.
    Journal
    |
    PARP2 (Poly(ADP-Ribose) Polymerase 2)
    |
    Partruvix (pamiparib)
    over1year
    Preclinical Study of Pamiparib, a CNS Penetrant PARP Inhibitor, in IDH1/2 Mutated Gliomas (CNS Mission 2022)
    No abstract available
    Preclinical • PARP Biomarker
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    Partruvix (pamiparib)
    almost2years
    Next-generation sequencing (NGS) for identifying actionable molecular alterations in newly diagnosed and recurrent IDHwt-glioblastoma (GBM) patients: A large mono institutional experience (ESMO 2022)
    All patients received radiotherapy and/or temozolomide as first line therapy...To date, 10% of patients received a personalized treatment as compassionate use, off-label use or in clinical trials (9 Dabrafenib/Trametinib, 8 Alpelisib, 3 Erdafitinib, 2 Ipatasertib, 1 Alectinib, 1 Capmatinib, 1 Palbociclib, 1 Entrectinib, 1 Pamiparib)...The activity analysis is ongoing. However, the incidence of actionable molecular alterations may differ between diagnosis and recurrent GBM samples.
    Clinical • Tumor mutational burden • PARP Biomarker • BRCA Biomarker • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • FGFR1 (Fibroblast growth factor receptor 1) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • CDK4 (Cyclin-dependent kinase 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    BRAF V600E • EGFR mutation • TMB-H • PIK3CA mutation • BRAF V600 • EGFR amplification • NF1 mutation • IDH wild-type • EGFR mutation + PTEN mutation
    |
    FoundationOne® CDx
    |
    Mekinist (trametinib) • Ibrance (palbociclib) • Tafinlar (dabrafenib) • Rozlytrek (entrectinib) • temozolomide • Alecensa (alectinib) • Piqray (alpelisib) • Balversa (erdafitinib) • ipatasertib (RG7440) • Tabrecta (capmatinib) • Partruvix (pamiparib)
    almost2years
    PNOC017: BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (clinicaltrials.gov)
    P1, N=78, Recruiting, University of California, San Francisco | Trial completion date: Jul 2027 --> Jul 2029 | Trial primary completion date: Jun 2022 --> Jun 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH2 mutation
    |
    temozolomide • Partruvix (pamiparib)
    almost2years
    Pamiparib for germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer. (PubMed, Drugs Today (Barc))
    Olaparib, rucaparib and niraparib are approved for various indications in epithelial ovarian cancer, fallopian tube or primary peritoneal cancer, while the PARP inhibitors for the treatment of breast cancer are olaparib and talazoparib. Pamiparib (Partruvix) is a new, selective inhibitor of PARP-1 and PARP-2 which was discovered by BeiGene Ltd. On April 30, 2021, pamiparib obtained its first registration worldwide--it was approved in China for the treatment of women with recurrent ovarian, fallopian tube or primary peritoneal cancer with confirmed germline BRCA mutation.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA (Breast cancer early onset) • PARP2 (Poly(ADP-Ribose) Polymerase 2)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Talzenna (talazoparib) • Zejula (niraparib) • Rubraca (rucaparib) • Partruvix (pamiparib)
    almost2years
    PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. (PubMed, Expert Opin Investig Drugs)
    While the advent of PARPis has significantly improved the treatment of tumors with defects in DNA damage and repair pathways, careful patient selection will be essential to enhance these treatments. The identification of molecular biomarkers to predict disease response and progression is an endeavor.
    Journal • Combination therapy • BRCA Biomarker • PARP Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA (Breast cancer early onset)
    |
    HER-2 negative • BRCA mutation
    |
    Lynparza (olaparib) • Talzenna (talazoparib) • Zejula (niraparib) • Rubraca (rucaparib) • veliparib (ABT-888) • Partruvix (pamiparib) • AiRuiYi (fluzoparib)